newsfilter
← Latest News
PR Newswire·

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Synaptogenix expecting data from its Phase 2 clinical trial of Bryostatin-1 for advanced Alzheimer's disease in fourth quarter 2022 NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging